林业发展局批准Amvuttra治疗罕见的心脏病,以减少死亡风险,但费用高昂。 FDA approves Amvuttra for a rare heart condition, reducing death risk but at a high cost.

林业发展局批准了Alnylam的新药Amvuttra,用于治疗由于有害的蛋白质积聚造成的心脏病 -- -- 心血管病(ATTR-CM)。 The FDA has approved Alnylam's new drug, Amvuttra, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by harmful protein buildup. 该药物在一项研究中将死亡和心脏问题的风险降低了28%。 The drug reduced the risk of death and heart issues by 28% in a study. 抗逆转录病毒药物每三个月服用一次,但费用昂贵,每剂量119 000美元,即每年476 000美元,可能限制许多病人获得治疗。 Amvuttra is administered every three months but is costly at $119,000 per dose, or $476,000 annually, potentially limiting access for many patients.